CO6190619A2 - DERIVATIVES OF 2- QUINOLINONA AND 2-QUINOXALINONA AND ITS USE AS ANTIBACTERIAL AGENTS - Google Patents

DERIVATIVES OF 2- QUINOLINONA AND 2-QUINOXALINONA AND ITS USE AS ANTIBACTERIAL AGENTS

Info

Publication number
CO6190619A2
CO6190619A2 CO09068489A CO09068489A CO6190619A2 CO 6190619 A2 CO6190619 A2 CO 6190619A2 CO 09068489 A CO09068489 A CO 09068489A CO 09068489 A CO09068489 A CO 09068489A CO 6190619 A2 CO6190619 A2 CO 6190619A2
Authority
CO
Colombia
Prior art keywords
6alkyl
6alkenyl
6alkynyl
optionally substituted
halo
Prior art date
Application number
CO09068489A
Other languages
Spanish (es)
Inventor
Janelle Comita-Prevoir
Marck Cronin
Bolin Geng
Andrew Aydon Godfrey
Folkert Reck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39046831&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6190619(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6190619A2 publication Critical patent/CO6190619A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Abstract

1.- Un compuesto de la fórmula (I):o una sal farmaceuticamente aceptable del mismo, en donde el compuesto de la fórmula es sustancialmente libre de una mezcla cis (±) de sus enantiómeros, y en donde A se selecciona a partir de CH y N; D se selecciona a partir de C- R7 y N; en donde al menos uno entre A y D es carbono; E se selecciona a partir de O, NH, y S, en donde: i) E es NH si R8 y R9 juntos forman =O; y ii) E es O o S si R8 y R9 son cada uno H; G se selecciona a partir de O y S; J se selecciona a partir de C- R4 y N; R1 se selecciona a partir de H, halo, ciano, C1-6alquilo, C2-6alquenilo, y C2-6alquinilo R1a y - N(R1a), en donde dichos C1-6alquilo, C2-6alquenilo, y C2-6alquinilo son opcionalmente sustituidos con uno o más R10;R1a en cada ocurrencia se selecciona independientemente a partir de H y C1-6alquilo, en donde dicho C1-6alquilo es opcionalmente sustituido con uno o más R20;R2 se selecciona a partir de halo, ciano, C1-6alquilo, C2-6alquenilo, C2-6alquinilo, -OR2a, -N(R2a) en donde dichos C1-6alquilo, C2-6alquenilo, y C2-6alquinilo son opcionalmente sustituidos con uno o más R20;R2a en cada ocurrencia se selecciona independientemente a partir de H y C1-6alquilo, en donde dicho C1-6alquilo es opcionalmente sustituido con uno o más R20; R3 se selecciona a partir de H, halo, ciano, C1-6alquilo, C2-6alquenilo, y C2-6alquinilo, OR3a y -N(R3a) 2, en donde dichos C1-6alquilo, C2-6alquenilo, y C2-6alquinilo son opcionalmente sustituidos con uno o más R30;R3a en cada ocurrencia se selecciona independientemente a partir de H y C1-6alquilo, en donde dicho C1-6alquilo es opcionalmente sustituido con uno o más R30;R4 se selecciona a partir de H, halo, ciano, -CO2H, C1-6alquilo, C2-6alquenilo, y C2-6 alquinilo, en donde dicho C1- 6alquilo, C2-6alquenilo, y C2-6alquinilo son opcionalmente sustituidos con uno o más R40;R6 se selecciona a partir de fluoro, C1-6alquilo, C2-6alquenilo, C2-6alquinilo, -OR6a, en donde dichos C1-6alquilo, C2-6alquenilo, y C2-6alquinilo son opcionalmente sustituidos con uno o más R60; ...1. A compound of the formula (I): or a pharmaceutically acceptable salt thereof, wherein the compound of the formula is substantially free of a cis (±) mixture of its enantiomers, and wherein A is selected from CH and N; D is selected from C-R7 and N; where at least one between A and D is carbon; E is selected from O, NH, and S, where: i) E is NH if R8 and R9 together form = O; and ii) E is O or S if R8 and R9 are each H; G is selected from O and S; J is selected from C-R4 and N; R1 is selected from H, halo, cyano, C1-6alkyl, C2-6alkenyl, and C2-6alkynyl R1a and -N (R1a), wherein said C1-6alkyl, C2-6alkenyl, and C2-6alkynyl are optionally substituted with one or more R10; R1a at each occurrence is independently selected from H and C1-6alkyl, wherein said C1-6alkyl is optionally substituted with one or more R20; R2 is selected from halo, cyano, C1-6alkyl , C2-6alkenyl, C2-6alkynyl, -OR2a, -N (R2a) wherein said C1-6alkyl, C2-6alkenyl, and C2-6alkynyl are optionally substituted with one or more R20; R2a at each occurrence is independently selected from of H and C1-6alkyl, wherein said C1-6alkyl is optionally substituted with one or more R20; R3 is selected from H, halo, cyano, C1-6alkyl, C2-6alkenyl, and C2-6alkynyl, OR3a and -N (R3a) 2, wherein said C1-6alkyl, C2-6alkenyl, and C2-6alkynyl are optionally substituted with one or more R30; R3a at each occurrence is independently selected from H and C1-6alkyl, wherein said C1-6alkyl is optionally substituted with one or more R30; R4 is selected from H, halo, cyano , -CO2H, C1-6alkyl, C2-6alkenyl, and C2-6 alkynyl, wherein said C1-6alkyl, C2-6alkenyl, and C2-6alkynyl are optionally substituted with one or more R40; R6 is selected from fluoro, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -OR6a, wherein said C1-6alkyl, C2-6alkenyl, and C2-6alkynyl are optionally substituted with one or more R60; ...

CO09068489A 2006-12-15 2009-07-02 DERIVATIVES OF 2- QUINOLINONA AND 2-QUINOXALINONA AND ITS USE AS ANTIBACTERIAL AGENTS CO6190619A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87018106P 2006-12-15 2006-12-15
US96916307P 2007-08-30 2007-08-30

Publications (1)

Publication Number Publication Date
CO6190619A2 true CO6190619A2 (en) 2010-08-19

Family

ID=39046831

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09068489A CO6190619A2 (en) 2006-12-15 2009-07-02 DERIVATIVES OF 2- QUINOLINONA AND 2-QUINOXALINONA AND ITS USE AS ANTIBACTERIAL AGENTS

Country Status (17)

Country Link
EP (1) EP2121702A1 (en)
JP (1) JP2010513255A (en)
KR (1) KR20090090385A (en)
AR (1) AR064369A1 (en)
AU (1) AU2007331247B2 (en)
BR (1) BRPI0720236A2 (en)
CA (1) CA2671485A1 (en)
CL (1) CL2007003641A1 (en)
CO (1) CO6190619A2 (en)
EC (1) ECSP099506A (en)
MX (1) MX2009006325A (en)
NO (1) NO20092655L (en)
PE (1) PE20081511A1 (en)
RU (1) RU2009126731A (en)
TW (1) TW200831517A (en)
UY (1) UY30788A1 (en)
WO (1) WO2008071961A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (en) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. Novel nitrogenated heterocyclic compound and salt thereof
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
AU2009302007B2 (en) 2008-10-10 2015-01-15 Actelion Pharmaceuticals Ltd Oxazolidinyl antibiotics
AR076222A1 (en) 2009-04-09 2011-05-26 Actelion Pharmaceuticals Ltd DERIVATIVES 2-HYDROXIETIL-1H-QUINOLIN-ONA AND ITS AZAISOTHERAL ANALOGS WITH ANTIBACTERIAL ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP2646567A4 (en) * 2010-10-04 2014-03-26 British Columbia Cancer Agency Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
US11440884B2 (en) * 2017-08-21 2022-09-13 Acadia Pharmaceuticals Inc. Compounds, salts thereof and methods for treatment of diseases
KR20200043409A (en) 2017-08-21 2020-04-27 아카디아 파마슈티칼스 인코포레이티드 Compounds for the treatment of diseases, salts and methods thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601265A1 (en) * 1996-01-16 1997-07-17 Bayer Ag 2-oxo and 2-thio-1,2-dihydroquinolinyl oxazolidinones
AR040336A1 (en) * 2002-06-26 2005-03-30 Glaxo Group Ltd PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE SUCH COMPOUND
JP5314244B2 (en) * 2004-10-27 2013-10-16 富山化学工業株式会社 Novel nitrogen-containing heterocyclic compounds and salts thereof
MY150958A (en) * 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (en) * 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. Novel nitrogenated heterocyclic compound and salt thereof
JP5171618B2 (en) * 2006-05-26 2013-03-27 富山化学工業株式会社 Novel heterocyclic compounds or salts thereof and intermediates thereof
WO2008006648A1 (en) * 2006-06-09 2008-01-17 Glaxo Group Limited Substituted 1-methyl-1h-quinolin-2-ones and 1-methyl-1h-1,5-naphthyridin-2-ones as antibacterials
GB0613208D0 (en) * 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) * 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
PE20081551A1 (en) * 2006-07-20 2009-01-09 Glaxo Group Ltd QUINOLONE DERIVATIVES AS ANTIBACTERIALS

Also Published As

Publication number Publication date
ECSP099506A (en) 2009-08-28
CL2007003641A1 (en) 2008-09-22
AR064369A1 (en) 2009-04-01
AU2007331247A1 (en) 2008-06-19
UY30788A1 (en) 2008-07-31
KR20090090385A (en) 2009-08-25
JP2010513255A (en) 2010-04-30
BRPI0720236A2 (en) 2013-12-24
EP2121702A1 (en) 2009-11-25
TW200831517A (en) 2008-08-01
NO20092655L (en) 2009-09-02
AU2007331247B2 (en) 2011-10-20
MX2009006325A (en) 2009-07-24
WO2008071961A8 (en) 2009-10-22
CA2671485A1 (en) 2008-06-19
RU2009126731A (en) 2011-01-20
WO2008071961A1 (en) 2008-06-19
PE20081511A1 (en) 2008-12-12

Similar Documents

Publication Publication Date Title
CO6190619A2 (en) DERIVATIVES OF 2- QUINOLINONA AND 2-QUINOXALINONA AND ITS USE AS ANTIBACTERIAL AGENTS
IS6902A (en) Non-aryl N-substituted heterocyclic NMDA / NR2B antagonists
ECSP055974A (en) SYNTHESIS OF CHLORIDES OF 4 AMINO-2-BUTENOIL AND ITS USE IN THE PREPARATION OF 3-CYANO QUINOLINAS
RS52168B (en) Piperidine gpcr agonists
DOP2012000149A (en) NEW TRYCLIC COMPOUNDS
ATE470662T1 (en) PIPERAZINYLPYRAZINE COMPOUNDS AS AGONISTS OR ANTAGONISTS AT THE SEROTONIN 5HT-2 RECEPTOR
CR9980A (en) IMIDAZOLINS 4,4,5,5 TETRASUSTITUIDAS
UY30499A1 (en) USEFUL DERIVATIVES OF AMINA AS ANTICANCERIGEN AGENTS
TNSN08407A1 (en) Organic compounds
CR8755A (en) FUSIONATED QUINOLIN DERIVATIVE AND USE OF THE SAME
ECSP099638A (en) NEW ADENINE COMPOUND
CR8744A (en) THERAPEUTIC COMPOUNDS
EA200870193A1 (en) CYTOTOXIC AGENTS, INCLUDING NEW TOMAMYCIN DERIVATIVES, AND THEIR THERAPEUTIC APPLICATION
MX2011012628A (en) Substituted aminopropionic derivatives as neprilysin inhibitors.
DE602008004265D1 (en) TRANS-3-azabicyclo-Ä3.1.0Ü-HEXANE DERIVATIVES
PE20051054A1 (en) HETEROCYCLIC COMPOUNDS USEFUL AS SECRETAGOGS OF GROWTH HORMONE
BRPI0821255A2 (en) Spiroindolinone Derivatives
DE602008001983D1 (en) PYRROLIDINE DERIVATIVES AS DOUBLE NK1 / NK3 RECEPTOR ANTAGONISTS
PE20140968A1 (en) SUBSTITUTED BENZAMIDE DERIVATIVES
GT200900026A (en) DERIVATIVES OF 5,6 -BISARIL-2-PIRIDIN-CARBOXAMIDA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS
NO20064175L (en) Heterocyclic compound
NO20071159L (en) Prodrug-substituted benzoxazoles as estrogenic agents
MX2009011365A (en) Bridged six-membered ring compounds.
NO20052023L (en) Calcium activated K channel opens with high conductance
PE20080207A1 (en) DERIVATIVES OF 1-N-AMINO-2-IMIDAZOLIDINONES AS INHIBITORS OF THE POTASSIUM CHANNEL Kv1.5

Legal Events

Date Code Title Description
FC Application refused